Interferon alpha kinoid

Drug Profile

Interferon alpha kinoid

Alternative Names: Antiferon; IFN-K - Neovacs; IFNα kinoid

Latest Information Update: 24 Jun 2017

Price : $50

At a glance

  • Originator Neovacs
  • Developer Department Immunology of Diabetes at Hospital Cochin; Neovacs; sanofi pasteur
  • Class Interferons; Vaccines
  • Mechanism of Action Immunomodulators; Interferon alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Dermatomyositis; Systemic lupus erythematosus
  • Preclinical Type 1 diabetes mellitus
  • Discontinued HIV infections; Sjogren's syndrome

Most Recent Events

  • 20 Jun 2017 Neovacs completes enrolment in its phase IIb trial for Systemic lupus erythematosus in Belgium, Chile, Colombia, Croatia, France, Georgia, Germany, Italy, Mexico, Moldova, Peru, Philippine, Poland, Russia, South Korea, Taiwan and Thailand and USA
  • 01 Mar 2017 Interferon alpha kinoid is available for licensing in USA, Europe as of 22 Feb 2017. http://neovacs.fr/en/
  • 21 Feb 2017 Biosense Global enters into license option agreement with Neovacs for Interferon alpha kinoid for Systemic lupus erythematosus and Dermatomyositis in China, Macau, Hong Kong, Taiwan and Singapore
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top